ArticlePloS one2025
One health approach unravels worrying antimicrobial resistance patterns: A cross-sectional study in Kisii, Kenya.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Community health volunteers as a frontline platform for antimicrobial resistance mitigation in sub-Saharan Africa: A scoping review.PLOS global public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance (AMR) is a major public health challenge, particularly in Sub-Saharan Africa, where diagnostic and surveillance capacities are limited. Enterobacterales significantly contribute to AMR, with environmental reservoirs facilitating transmission between humans, animals, and the environment.
methodsThis study investigated the prevalence and antimicrobial susceptibility of selected Enterobacterales in human, water, animal feces, and soil samples in Kenya. A cross-sectional study including 200 patients with gastrointestinal symptoms was conducted at Kisii Teaching and Referral Hospital and surrounding areas. AMR testing was performed using the disk diffusion method.
resultsA total of 365 samples were collected: 200 human and 55 each of water, animal feces, and soil specimens from the homesteads of patients with resistant isolates. 343 isolates were obtained (Escherichia coli: 280/343 [81.6%], Salmonella spp.: 28/343 [8.2%], Klebsiella spp.: 25/343 [7.3%], Shigella spp.: 10/343 [2.9%]). A significant proportion of isolates exhibited AMR, particularly to piperacillin-tazobactam (up to 87%) and ampicillin (up to 79%). Resistance to piperacillin-tazobactam in E. coli was the highest, observed in humans (100/139, 71.9%), water (42/49, 85.7%), animal feces (9/46, 19.6%), and soil (33/46, 71.7%). Almost half (45%) of the human isolates showed ESBL production or resistance to imipenem, with water, animal feces, and soil samples, revealing similar resistance patterns. Resistance to chloramphenicol (71.7% vs 20.1%; p < 0.001) and third-generation cephalosporins were higher among animal and environmental isolates (animal feces: cefotaxime - 25/46, 54.3%; ceftazidime - 27/46, 58.7%) as compared to human isolates (cefotaxime - 40/139, 28.8%; ceftazidime - 28/139, 20.1%) (p < 0.001). In human isolates, the most prevalent genes were blaTEM (53/187, 28.3%), blaOXA-48 (43/187, 23.0%), blaSHV (32/187, 17.1%), and blaCTXM-15 (41/187, 21.9%); in animal isolates, blaCTXM-8 (11/55, 20.0%), blaVIM (8/55, 14.5%), and blaTEM (8/55, 14.5%) were most detected; while in soil and water isolates, blaCTXM-8 was the most common (10.9% and 9.1% respectively).
conclusionShared resistance patterns across human, animal, and environmental samples highlight interconnected AMR pathways. These findings reinforce the need for a One Health approach through integrated AMR surveillance and interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.